Search Results

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, Human Acellular Vessels at commercial scale, announced the issuance of four new ICD-10-PCS codes by the U.S. Centers for Medicare & Medicaid Services ICD-10 Coordination and Maintenance Committee.

CGI Federal Inc., a wholly-owned U.S. operating subsidiary of CGI Inc., has been awarded a single award, firm-fixed price contract by the Centers for Medicare & Medicaid Services to help improve access to Medicare for millions of beneficiaries by modernizing the agency’s Health Plan Management System.

The Centers for Medicare & Medicaid Services revised the National Coverage Determination of allogeneic hematopoietic stem cell transplantation for individuals with myelodysplastic syndromes due to a request for reconsideration prepared by The American Society of Hematology, the American Society for Transplantation and Cellular Therapy®, the National Marrow Donor Program, and the Center for International Blood and Marrow Transplant Research on January 5, 2024.

The adjusted guidelines will provide drugmakers with more opportunities to engage with the Centers for Medicare and Medicaid Services regarding the initial maximum fair price offers, according to the agency.

Invivyd, Inc. announced that the U.S. Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System Q code covering product reimbursement for PEMGARDA.

For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.

Verrica Pharmaceuticals Inc. announced that the Centers for Medicare & Medicaid Services has issued a permanent J-Code for YCANTH™, which is the only FDA-approved treatment for molluscum contagiosum.

Endologix LLC announces that the U. S. Centers for Medicare & Medicaid Services granted a Transitional Pass-Through Payment for the DETOUR System, effective January 1, 2024.

Celularity Inc. announced that the U.S. Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System Q code for Biovance® 3L, a tri-layer allograft derived from placental tissue intended for use as a biological membrane covering barrier or wrap that acts as a scaffold for restoration of functional tissue in partial- and full-thickness, acute and chronic wounds.